Abstract The present study reports on a new strategy for selective, radiation therapy-amplified drug delivery using an antiangiogenic 33-a.a., tumor vasculature-targeting ligand, anginex, to improve the therapeutic ratio for strategies developed against solid tumors. Our findings indicate that galectin-1 is (a) one of the major receptors for anginex (b) overexpressed by tumor neovasculature and (c) further specifically upregulated in endothelial cells in response to radiation exposure as low as 0.5 Gy. An investigation of [18]-F-labeled anginex biodistribution in SCK tumors indicates that anginex is an effective targeting molecule for image and radiation-guided therapy of solid tumors. An anginexconjugated liposome capable of being loaded with drug was shown to selectively target endothelial cells postradiation. The presence of endothelial cells in a threedimensional co-culture system with tumor cells developed to study tumor/endothelial cell interactions in vitro led to higher levels of galectin-1 and showed a further increase in expression upon radiation exposure when compared to tumor cell spheroids alone. Similar increase in galectin-1 was observed in tumor tissue originating from the tumor-endothelial cell spheroids in vivo and radiation exposure further induced galectin-1 in these tumors. The overall results suggest feasibility of using a clinical or subclinical radiation dose to increase expression of the galectin-1 receptor on the tumor microvasculature to promote delivery of therapeutics via the anginex peptide. This approach may reduce systemic toxicity, overcome drug resistance, and improve the therapeutic efficacy of conventional chemo/radiation strategies.
Introduction
One of the primary goals of a successful cancer treatment regimen is to deliver an effective combination of radiation and/or drugs to tumors while minimizing damage to normal tissues. Tumor growth is essentially considered to be directly dependent on its blood supply. Several unique proteins functionally important to tumor angiogenesis are expressed on tumor-endothelial cells and can serve as potential targets for drug delivery to solid tumors. Radiation has also been found to achieve site-specific expression or upregulation of receptor(s) within tumors which are now being considered as ligands for targeted drug delivery [1, 2] . Since approximately 50-60 % of patients receiving radiation receive concomitant chemotherapy at present, with this number continuously increasing, targeting drug delivery to the tumor vasculature by radiation-induced receptor expression on endothelial cells is a very promising approach. The 14.5-kDa protein, galectin-1, shown to be involved in tumor angiogenesis has been found to be upregulated in the tumor microenvironment [3] of colon [4] , prostate [5] , bladder [6] , and breast [7] cancers. Our recent findings establish that the already elevated galectin-1 expression in the tumor stroma further increases, after radiation exposure, particularly on the endothelial cell surface.
Targeting the tumor vasculature is a strategy that can therefore allow targeted delivery to a wide range of tumor types [8, 9] . The past two decades has given rise to an emerging literature establishing galectin-1 as an important protein in cancer biology that is enriched in the tumorassociated neovascular endothelium [10] [11] [12] [13] and has identified the 33-amino acid antiangiogenic anginex peptide [14, 15] to specifically bind and inhibit the function of galectin-1 receptor [11] [12] [13] 16] . The dual targeting effect of anginex and α(v)β [3] integrin RGD, another angiogenesis-specific ligand, has recently been reported for molecular imaging of angiogenesis [17, 18] and has indicated the potential for targeted drug delivery. We are the first, to our knowledge, to elucidate in this study the effect of radiation exposure on induction of galectin-1 expression in the endothelial cells and the tumor vasculature in vivo. We have observed an induction in galectin-1 expression at radiation dose as low as 0.5 Gy. Such low subclinical doses of ionizing radiation may be effectively used to "prime" the target, galectin-1 in the tumor-associated endothelium for drug delivery via anginex or galectin-1-specific antibody. Our present and earlier studies with [18] -F-labeled anginex biodistribution and anginex-conjugated liposome uptake suggested that anginex could be an effective targeting molecule for image and radiation-guided therapy of solid tumors [19, 20] . We therefore hypothesized that delivery of nanosized chemotherapies via the anginex peptide targeted to radiationinduced, tumor vasculature-associated galectin-1 would allow for preferential targeting to the tumor site.
We have also studied the expression of galectin-1 upon radiation exposure in a three-dimensional co-culture system of tumor and endothelial cells grown in hanging drops of medium that more closely simulates the tumor/tumor microenvironment in vivo. The presence of endothelial cells in the co-culture enhances the expression of radiation-induced galectin-1 and protects tumor cells from radiation-induced cell death [21] . Similar pattern of galectin-1 expression is observed when these tumor-endothelial cell co-cultures are implanted in vivo. Future work will incorporate this murine breast cancer model in developing our strategy for radiationguided drug delivery. Results from the current study lay the foundation for the development of a chemoradiation strategy where we can exploit clinically relevant radiation doses for enhanced drug delivery with reduced side effects and comorbidities and an improved therapeutic ratio.
Materials and methods

Antibodies and reagents
The galectin-1 (sc-19277) and actin (sc-1616) antibodies were from Santa Cruz Biotechnology and the CD34 (cat. no. 553731) antibody was from BD Pharmingen. Anginex was obtained from the biochemical facility of the University of Minnesota as a lyophilized powder and reconstituted in water for in vitro experiments or methanol for PET imaging. All other solvents or reagents were purchased from Fischer Scientific and Sigma-Aldrich unless otherwise noted. The ProteoExtract Native Membrane Protein Extraction kit (cat. no. 444810) was purchased from Calbiochem.
Cell lines and culture
The EA.hy926 human and 2H11 murine endothelial cell lines and MDA-MB-231 human breast adenocarcinoma cell line were obtained from American Type Culture Collection. Human umbilical vein endothelial cells were bought from Lifeline Cell Technology. Isolation and culture of microvascular endothelial cells were as described [22] . The endothelial progenitor cells were isolated and cultured as described [23] . Green fluorescent protein (GFP)-4T1 murine epithelial carcinoma and the SCK murine mammary carcinoma cell lines were kind gifts from Dr. Alexander Asea (Texas A&M Health Science Center, Temple, TX) and Dr. C Song (Masonic Cancer Institute, Minneapolis, MN), respectively. The cell lines were maintained in monolayer culture at 37°C and 5 % CO 2 . The MDA-MB-231, GFP-4T1, and 2H11 cell lines were cultured in Dulbecco's minimal essential medium (DMEM, Cellgro), supplemented with 10 % fetal bovine serum (Atlas) and 1 % penicillin/streptomycin (Hyclone). The EA.hy926 cells were maintained in DMEM/F12 with 10 % bovine calf serum, 2 % hypoxanthine-aminopterinethymidine medium (Cellgro). The SCK tumor cell line was grown in RPMI 1640 (Hyclone) and supplemented with 10 % bovine calf serum (Atlas Biologicals) and 1 % penicillin/streptomycin (Hyclone).
Membrane and whole cell lysates
Whole cell extracts were prepared by suspending cells in 0.25 ml of lysis buffer (25 mM HEPES, pH7.5, 0.5 % sodium deoxycholate, 5 mM EDTA, 5 mM dithiothreitol, 20 mM glycerophosphate, 1 mM Na3VO4, 50 mM NaF, 1 % Triton X-100, 20 μg/ml aprotinin, 50 μg/ml leupeptin, 10 μM pepstatin, 1 μM okadaic acid, and 1 mM phenylmethylsulfonyl fluoride). The lysates were incubated at 4°C with gentle agitation on a rocker plate (Mini Mixer, Benchmark Research Products, NY) for 1 h and cell debris was removed by centrifugation (15 min at 12,000×g). The protein concentration in the supernatant was determined using the bicinchoninic acid (BCA) protein assay kit (Pierce).
Extraction of membrane fraction
The membrane protein fraction was extracted using the Native Membrane Protein Extraction kit (Calbiochem) according to the manufacturer's suggested protocol. The supernatant-containing membrane protein was collected and stored at -80°C for future analysis. Protein concentrations of the membrane fraction obtained were determined using the BCA protein assay kit (Pierce).
Western blot analysis
Immunoblotting was performed with an antibody against galectin-1 and actin (Santa Cruz Biotechnology, CA) and the CD34 (BD Pharmingen).
Spheroid culture in "hanging drop" GFP-4T1 tumor cells and 2H11 endothelial cells were used to generate multicellular spheroids by growing them as hanging drops of medium (in DMEM with 10 % FBS and antibiotic/anti-mycotic mix) [21] . 
Experimental radiation
Radiation was carried out in CP 160 X-ray system (Faxitron X-ray Corporation Tucson, AZ, USA). The instrument may be operated at different peak kilovoltages, shelf height (solid state drives (SSD)), filtration thickness, and electrically operated turntable to ensure uniform dosing. For all experiments, shelf-6 (SSD043.2 cm covering, ∼39 cm diameter field, and 0.8 mm Be/0.5 mm Cu filtration) was used with 150 kVp and 6 mA beam. Dosimetry was carried out using a pinpoint ion chamber (PTW N301013, ADCL calibrated for 225 kV) following the AAPM TG-61 protocol [24] . The radiation dose rate in our setup was 1.018±0.10 Gy/min at 150 kV and 6.6 mA. Mice were anesthetized with isoflourane and flank irradiation was carried out with a custom cut lead shielding jig covering the animal, except for the tumor-bearing extremity. [19] . It was then used to label anginex via reductive amination as described [19] .
MicroPET imaging -SCK Tumors
To detect the [
18 F]anginex uptake by the SCK tumor, 2-h static microPET imaging was performed in five tumor graft-bearing mice after injection with 1.1 MBq (30 μCi) of [
18 F]anginex tracer in a solution of 10 mg/ml of unlabeled anginex. Static scans of the tracer using UAMS microPET Focus 220 (Concorde Microsystems, Knoxville, TN) were captured for 20 min through the tumor region before and after the radiation exposure. PET data were iteratively reconstructed with the ordered subset expectation maximization algorithm. The tracer uptake was reported as mean standardized uptake value, which was calculated as the radioactivity of the region of interest divided by the injected dose per animal body weight. Activities within the tumor were normalized to the total body activity.
Preparation of anginex-conjugated fluorescent liposomes
Liposomes with a diameter of approximately 150 nm that were prepared had a basic formulation consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and DSPE-PEG (amine 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-Depa) or DSPE-PEG-maleimide (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000]), with molar ratios 1.1:1:0.075. The liposomes were rendered fluorescent by the addition of ∼0.1 mol% fluorochrome (Texas Red 1,2-dihexadeconoylsn-glycero-phosphoethanolamine). The liposomes were prepared by extrusion through nuclear filters with the appropriate pore size. A low immunogenic response was assured by the PEG functionalization of these lipids. The liposomes size distribution was analyzed by using a dynamic light scattering particle size analyzer (Brookhaven Instruments Corporation, Holtsville, NY). The liposome functionalization with anginex peptides was made using the maleimide moieties attached to the end of the DSPE-PEG-maleimide lipids and the additional cysteine at the anginex N-terminal. The maleimide group reacts specifically with sulphydryl groups of the peptide and forms a stable thioether bond. The unreacted peptide was removed by overnight dialysis. The presence of anginex on the liposomal surface was established by zeta potential measurements (Zeta-Pals facility, University of Arkansas, Fayetteville, AR).
Flow cytometry
Acquisition and analysis of data were performed using an EPICS1XLTM flow cytometer (Beckman Coulter, Fullerton, CA). For each cell line, viable cell size scatter dot plot was gated for control nontargeted liposome sample and bars were set in FL3 channel for background area, shifted area, and whole area, and protocol was saved and applied to all samples in the experiment. The x-median 50 values of the whole area were used for comparisons.
Diaminobenzidine tetrahydrochloride immunohistochemistry
Tumors were fixed in 10 % neutral buffered formalin and embedded in paraffin. Five-micrometer sections were immunostained with Hypoxyprobe-1 kit (HPI, Burlington, MA) according to manufacturer's recommendations. Tissue imaging was performed using an Aperio Scanscope (Aperio, Vista, CA) at ×20 magnifications and analyzed using Imagescope software (Aperio, Vista, CA). Necrotic areas, tissue folds, and borders were excluded from analyses and remaining viable tissue was analyzed for diaminobenzidine tetrahydrochloride (DAB) using an algorithm preconfigured to quantify brown color in three intensity ranges (weak, medium, and strong).
Statistical analysis
The results are expressed as the means±SD, and the significance of differences was evaluated by Student's t test using SPSS (version 15.0) software (SPSS Inc., Chicago, IL, USA). Values were considered statistically significant when P<0.05.
Results
Elevated expression of galectin-1 in tumors from different tissue origin and microPET imaging of anginex uptake by SCK tumors which is further augmented upon radiation exposure
To investigate the expression pattern of galectin-1 in human tumor and normal tissues and establish the validity of our targeting strategy, human lung, bladder, and breast tumor specimens and the corresponding normal tissues were examined by western blot analysis. A 4-, 4.75-, and 2.2-fold increase in galectin-1 expression was observed in the lung, bladder, and breast tumor tissues, respectively, when compared to their corresponding normal tissues (Fig. 1a) .
We have developed a method to label anginex with [18] -F and established its use for imaging of tumors in myeloma models [19] . Figure 1b demonstrates anginex uptake before and after a typical clinical radiation dose of 2 Gy in murine mammary SCK tumors in vivo using the microPET imaging strategy. Radiation exposure increased uptake by an average of 141±49 % a substantial increase in terms of clinical PET (significance is typically regarded as a 30 % change in standardized uptake value in solid tumors [25] ). Figure 1c shows a time course of anginex uptake by the SCK tumor and normal muscle tissue in A/J mice. The A/J mice were injected with 0.86 mCi of total activity with a significant amount taken up by the tumor tissue over the first 45 min post-injection.
We have also generated new evidence in the laboratory that human tumor xenografts in SCID mice express galectin-1, and that treatment with anginex and/or radiation modifies its expression in the tumor (Fig. 2a) [20] . Digital quantification of the images in Fig. 2b showed a ∼50 % increase in the positive staining upon radiation exposure (upper panel) and ∼tenfold increase in strong positive staining for galectin-1. Addition of anginex treatment to radiation markedly reduced the amount of staining (lower panel) indicating the inability of the antibody to bind to galectin-1 because of its binding to anginex and/or the destruction of cells expressing gal-1 after anginex and radiation treatment. This competitive binding of anginex and galectin-1 antibody or loss of galectin-1 expression caused reduced immunostaining of the tumor with galectin-1 antibody.
Targeting of anginex-conjugated liposomes to tumor and endothelial cells upon radiation exposure via anginex-galectin-1 binding
We have found increased expression of galectin-1 in the membrane fractions of different human endothelial cell (Fig. 3a, b with loading control in Supplemental Fig. 1 ) and 2H11 murine endothelial cell line (Fig. 3c ) upon exposure to radiation doses as low as 0.5 Gy. This increase is, however, not observed in the breast cancer cell line, MDA-MB-231 (Fig. 3a, last panel) . A liposomal formulation including fluorescently tagged lipids and a covalent linkage using maleimide of bioactive anginex [26] on the surface was developed as illustrated in Fig. 4a . Studies with "anginex-tagged" liposomes subsequently indicated significant binding and uptake of the carrier by endothelial and tumor cells in culture. There was a gradual increase in uptake of anginex-conjugated fluorescent liposomes with increasing dose and duration of incubation with 2H11 endothelial cells (Fig. 4b) . Figure 4c shows the difference in binding of anginex-tagged liposomes to 2H11 endothelial cells compared to liposomes only. This binding of the anginex-tagged liposomes increased specifically on endothelial cells after exposure to 2 and 4 Gy radiation (Fig. 5a,  b) and not in the SCK tumor cells upon radiation exposure, supporting observations made with our in vitro results. Nontagged liposomes exhibit little to no binding to either cell type before or after radiation. Furthermore, the addition of either free anginex or anti-galectin-1 antibody to the 2H11 endothelial cells along with the targeted liposomes blocked uptake by ∼50 % in general and specifically blocked the radiation-induced uptake in the 2H11 endothelial cells, suggesting a galectin-1-mediated pathway for anginexconjugated liposome binding (Fig. 5c, d ). This correlated with our previous results that indicated expression of galectin-1 increases in response to radiation in the membranous fraction of the 2H11 murine endothelial cell type (Fig. 3c) .
Elevated galectin-1 in murine tumor-endothelial cell spheroids that is further enhanced upon radiation
In the three-dimensional multicell co-culture system that we have developed to capture the interaction between tumor and endothelial cells, we investigated the response of GFPexpressing 4T1 mouse mammary tumor cells and the 2H11 murine endothelial cells to radiation exposure. Figure 6a shows a GFP-expressing 4T1-2H11 tumor-endothelial cell spheroid 10 days post-culture in a hanging drop of medium (i and ii). The galectin-1 expression was found to be elevated in 4T1-2H11 tumor-endothelial cell spheroids as compared to 4T1 tumor cell only spheroids which were further enhanced in the tumor-endothelial cell 4T1-2H11 cell spheroids upon exposure to 4 Gy of radiation (Fig. 6b) . This galectin-1 expression was also was also found to be elevated in lysates of tumors originating from the tumor-endothelial cell spheroids growing in window chamber implants of nude mice (Fig. 6c) . Induction of galectin-1 expression upon radiation exposure was also observed in tumors generated from tumor-endothelial cell spheroids in the rear limb of nude mice (Fig. 6d) .
Discussion
Galectin-1 expression has been found to be elevated in inflamed and neoplastic tissues. It is expressed on the surface of activated endothelium, stromal fibroblasts, tumor cells, and antigen-presenting cells of the neoplastic tissue [5, [27] [28] [29] [30] . Studies reported in literature indicate that galectin-1 is overexpressed in the tumor and surrounding tissue, "the tumor stroma," and its increase is related to tumor progression, immune escape, and metastasis [3] . However, because it is regulated by several factors, its expression levels in different cell types constituting the tumor/tumor microenvironment tend to vary. Hypoxia inducible factors like HIF-1α [31, 32] , soluble factors secreted by tumor cells [28] , and radiation inducible factors which might also be endothelial cell-specific like Egr-1 [33, 34] may also play a role in enhancing the expression of galectin-1 on the endothelial cell surface. A schematic depicting the possible regulation of galectin-1 in tumor and endothelial cells by radiation is shown in Supplemental Fig. 2 . It is possible that the effects of radiotherapy on the tumor microenvironment maximally stimulate the signaling pathways involved in galectin-1 expression, secretion, and possibly function on the inside, outside, or even distant from the tumor cell. For instance, the expression of HIF-1α has been clearly established to be stimulated in endothelial cells by the stress of ionizing radiation exposure [35] and is a driver of galectin-1 expression [36] . Furthermore, the idea that galectin-1 might be used by tumor cells to promote progression and growth has been elegantly established by Griffioen and his group [10] . Therefore, our results suggest that ionizing radiation exposure can exploit these phenomena to create a favorable target expression and location for delivery of other therapeutics or imaging probes.
We have shown in Figs. 1, 2 , and 3 that galectin-1 is upregulated in three different human tumors and that galectin-1 expression can be selectively augmented by radiation exposure in endothelial cells. The uptake of galectin-1-specific isotope-labeled anginex peptide was shown to be high in tumors. This uptake further increased after radiation (Figs. 1, 2 , and 3) in a manner that suggests that a ratio of tenfold or greater galectin-1 expression between tumor-endothelial cells and normal tissue may be obtained for targeting or imaging the tumor via the vasculature with our approach. The uptake of anginex-conjugated fluorescent liposomes was also found to be increased significantly in the murine endothelial cell line (2H11) upon radiation exposure. This increase was not observed in the murine mammary SCK tumor cell line (Figs. 4 and 5) . Finally, the murine breast cancer co-culture model that we have developed also showed a similar trend of galectin-1 expression as observed in vivo (Fig. 6 ). These studies have led us to infer that anginex is capable of serving as ligand for carrying conjugated drug-loaded nanoparticles to the tumor vasculature-associated receptor, galectin-1, especially with the use of radiation exposure as a means to specifically augment the targeting and/or as a by-product of radiation exposure that occurs during normal radiotherapy.
The data presented in Fig. 3 are an important aspect of our current findings. The standard dose of radiotherapy on a daily basis for patients is 2 Gy or higher. However, our data suggest that there may be reason to consider using very low doses of ionizing radiation to prime the target in the tumorassociated endothelium. In Fig. 3 , we performed a dose response with low doses and found that after only 0.5 Gy (the lowest dose studied), the expression of galectin-1 increased as much or more than higher doses up to 4 Gy in a variety of endothelial cell types. We surmise from this data that a low dose of conformal radiation may improve the ability to target anginex-conjugated liposomes to the known tumor volume via the tumor vasculature for drug delivery or imaging contrast. In addition, the idea that a low dose of total body radiation could be used to stimulate the galectin-1 expression in not only the primary but other metastatic lesions that are known or unknown at the time of treatment. With this approach, highly effective systemic therapy may also be developed based on targeting only tumor-associated endothelial cell galectin-1 expression. Regardless, at the present time, concurrent chemotherapy and radiation therapy are the standard of care for most types of cancers. Since the already elevated levels of galectin-1 can be further increased by radiation exposure, the targeting of galectin-1 protein for tumor-specific drug delivery appears to be a promising strategy for the treatment of a wide variety of solid tumors.
